Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and oral formulations of tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA date for both applications is June 20.

The committee will also discuss an NDA from Durata Therapeutics Inc. (NASDAQ:DRTX) for IV dalbavancin (RQ-00000002) to treat ABSSSIs. Dalbavancin has a May 26 PDUFA date.

Durata gained $1.35 (12%) to $12.77 on the week.

Durect Corp. (NASDAQ:DRRX) slid $0.40 (21%) to $1.55 on Thursday after FDA issued a complete response letter for an NDA for Posidur bupivacaine to treat postoperative pain. According to Durect, FDA said additional safety studies need to be conducted.

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX), which markets Exparel for postoperative pain, was up $8.23 (13%) to $70.10 on Thursday. Exparel is a bupivacaine liposome extended-release injectable suspension.

Durect was off $0.43 (21%) to $1.65 on the week, while Pacira gave back some of its gains to finish up $3.77 to $68.02.

Gilead Sciences Inc. (NASDAQ:GILD) added $2.46 to $81.21 last

Read the full 1846 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers